Clinical Trials Browser

Phase 1/2 × Erlotinib Hydrochloride × Genitourinary × Clear all

Prostatic Neoplasms

NCT00522249 2016-03-17

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Phase 1/2 Terminated

10 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Phase 1/2 Completed

66 enrolled

CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00193258 2013-01-31

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Phase 1/2 Completed

94 enrolled 7 charts

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma